The Conversation (0)
Zafgen (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering will be sold by Zafgen. As quoted in the press release: …
Zafgen (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering will be sold by Zafgen.
As quoted in the press release:
In addition, Zafgen intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.
Cowen and Company, LLC and Piper Jaffray & Co. are serving as joint book-running managers for the offering, and JMP Securities LLC and Wedbush Securities Inc. are serving as co-lead managers. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.